Jason Butler
Stock Analyst at Citizens
(4.67)
# 169
Out of 5,182 analysts
142
Total ratings
51.7%
Success rate
47.09%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Market Outperform | $52 | $12.86 | +304.35% | 1 | Apr 6, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $60.69 | +58.18% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $4.20 | +90.48% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $2.91 | +552.92% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $109.87 | +19.23% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $11.51 | +65.07% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $63.86 | +44.07% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.09 | +193.40% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $33.74 | -17.01% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.67 | +63.21% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $19.85 | +96.47% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.02 | +49.25% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $23.23 | +330.48% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $13.61 | +179.21% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.90 | +81.82% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.91 | +109.42% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $775.03 | -9.55% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.07 | +193.16% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.57 | +150.99% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.44 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $5.45 | +770,542.20% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.75 | +743.64% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.15 | +116.87% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.70 | - | 1 | Dec 2, 2020 |
Avalo Therapeutics
Apr 6, 2026
Initiates: Market Outperform
Price Target: $52
Current: $12.86
Upside: +304.35%
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $60.69
Upside: +58.18%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $4.20
Upside: +90.48%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $2.91
Upside: +552.92%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $109.87
Upside: +19.23%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $11.51
Upside: +65.07%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $63.86
Upside: +44.07%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.09
Upside: +193.40%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $33.74
Upside: -17.01%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.67
Upside: +63.21%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $19.85
Upside: +96.47%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.02
Upside: +49.25%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $23.23
Upside: +330.48%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $13.61
Upside: +179.21%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.90
Upside: +81.82%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.91
Upside: +109.42%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $775.03
Upside: -9.55%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.07
Upside: +193.16%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.57
Upside: +150.99%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.44
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $5.45
Upside: +770,542.20%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.75
Upside: +743.64%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.15
Upside: +116.87%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $2.70
Upside: -